The mechanisms by which SGLT2 inhibitors improve HF outcomes are still being investigated, presumably involving regulation on hemodynamics [17, 18], myocardial energy and loading, endothelial function and inflammation, and progression of renal disease [18–21]. Here, SLC5A2 is linked to kidney disorder.